About This Calculator
The Empliciti (elotuzumab) Dosing Calculator is a clinical tool designed for healthcare professionals to determine the appropriate dose and volume of Empliciti for patients with multiple myeloma. This tool simplifies calculations based on patient weight and the specific treatment regimen, ensuring accuracy in accordance with the FDA-approved prescribing information.
Outputs
Upon entering the required patient data, the calculator provides the following key outputs:
- Total Empliciti Dose (mg): The precise, weight-based dose of elotuzumab to be administered.
- Total Volume (mL): The corresponding volume of the reconstituted solution (at a concentration of 25 mg/mL) needed to achieve the calculated total dose.
- Dosing Summary: A confirmation of the inputs used for the calculation, including patient weight (in both kg and lbs), the selected treatment regimen, and the relevant treatment cycle.
How to Use
To ensure an accurate dose calculation, please follow these steps:
- Enter Patient Weight: Input the patient's current weight. You can toggle between kilograms (kg) and pounds (lbs) for convenience.
- Select Treatment Regimen: Choose the appropriate combination therapy from the dropdown menu:
- In combination with lenalidomide and dexamethasone.
- In combination with pomalidomide and dexamethasone.
- Select Treatment Cycle (if applicable): If the pomalidomide-based regimen is selected, an additional field will appear. Specify whether the patient is in Cycles 1 and 2 or in Cycle 3 and subsequent cycles, as the dosing differs.
- Calculate: The tool automatically calculates and displays the results as you input the information. Review the output to confirm the dose before preparation.
Dosing Overview
The recommended dosage of Empliciti is based on the combination regimen being used:
- With Lenalidomide and Dexamethasone: The recommended dose is 10 mg/kg administered intravenously every week for the first two cycles, and every 2 weeks thereafter.
- With Pomalidomide and Dexamethasone: The dosing schedule is different.
- For Cycles 1 and 2: 10 mg/kg intravenously every week.
- For Cycle 3 and beyond: 20 mg/kg intravenously every 4 weeks.
Administration requires pre-medication to reduce the risk of infusion-related reactions. Always refer to the full prescribing information for complete details on administration, infusion rates, and pre-medication requirements.
Switching Therapy
This calculator is not designed to provide guidance on switching between different multiple myeloma therapies. Clinical decisions regarding treatment changes should be based on a comprehensive patient assessment, current clinical guidelines, and the full prescribing information for any new agents being considered.
Missed Dose
If a planned dose of Empliciti is missed, it should be administered as soon as possible. The schedule of administration should then be adjusted accordingly to maintain the recommended dosing interval. Consult the official prescribing information for specific guidance on schedule adjustments.
Safety Alerts
Infusion-Related Reactions (IRRs): Empliciti can cause IRRs. Pre-medication with dexamethasone, H1 and H2 blockers, and acetaminophen is required prior to infusion to minimize this risk. Monitor patients during and after infusion.
Infections: Increased risk of infections, including opportunistic infections, has been observed. Monitor patients for signs and symptoms of infection and treat promptly.
Secondary Primary Malignancies: An increase in invasive secondary primary malignancies has been seen in patients treated with elotuzumab in combination with lenalidomide and dexamethasone. Monitor patients for the development of SPMs.
This is not a complete list of safety information. Please refer to the full Prescribing Information for all warnings and precautions.
Frequently Asked Questions
The dosing for the pomalidomide combination (10 mg/kg for cycles 1-2, then 20 mg/kg for cycle 3+) was established in the ELOQUENT-3 clinical trial. This specific schedule was found to be effective and is the FDA-approved dosing for this regimen.
No. This tool calculates the standard, recommended dose based on weight and regimen. It does not provide recommendations for dose modifications or interruptions due to adverse reactions. Consult the "Dosage and Administration" section of the full prescribing information for guidance on managing toxicity.
After reconstitution with Sterile Water for Injection, the final concentration of the Empliciti solution in the vial is 25 mg/mL. The calculator uses this concentration to determine the total volume needed for the patient's dose.
The prescribing information does not specify a maximum dose or dose capping based on weight. The dose is calculated strictly based on the patient's actual body weight at the recommended mg/kg rate.
The tool defaults to "Cycles 1 and 2," which corresponds to the 10 mg/kg dose. It is critical to select the correct cycle to ensure the accurate dose (10 mg/kg vs. 20 mg/kg) is calculated for patients on the pomalidomide regimen.
The prescribing information states that no dose adjustment is necessary for patients with mild to moderate renal impairment or mild hepatic impairment. Data for severe impairment is limited. This tool calculates the standard dose, and any adjustments should be made based on clinical judgment and the latest prescribing information.
Pre-medication is required to reduce the incidence and severity of infusion-related reactions (IRRs), which are a known risk with Empliciti. The standard pre-medication regimen must be administered 45 to 90 minutes before every infusion.
This warning appears for very high or very low weights to prevent errors from typos. Please double-check the patient's weight and the selected unit (kg or lbs) to ensure the input is accurate before proceeding.
References
- EMPLICITI® (elotuzumab) for injection, for intravenous use. U.S. Prescribing Information. Bristol-Myers Squibb Company. Rev. October 2023.
- Empliciti (elotuzumab) Dosing & Administration. Bristol Myers Squibb HCP Portal. Accessed 2024.
- Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma (ELOQUENT-3): a randomised, open-label, phase 2 trial. Lancet Haematol. 2018;5(11):e511-e521. doi:10.1016/S2352-3026(18)30149-1
- Empliciti (elotuzumab) European public assessment report (EPAR). European Medicines Agency. Accessed 2024.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com